SEMA4B, His, Human
| $320.00 | |
| Z05802-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $320.00 | |
| Z05802-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 75.8 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 80-110 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of SEMA4B, His, Human is greater than 95% as determined by SEC-HPLC. »
SEMA4B, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC. |
| Synonyms | Semaphorin-4B; Semaphorin-C; SEMA4B; KIAA1745; SEMAC; MGC131831; SemC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.